What are the top-selling drugs of Roche?

Overview of Roche Pharmaceuticals

Roche, founded in 1896 in Basel, Switzerland, is not only one of the oldest but also one of the most innovative and influential companies in the global biotechnology sector. Initially launched as one of the first industrial manufacturers of branded medicines, Roche has evolved into a global leader with a dual focus on pharmaceuticals and diagnostics. This unique combination allows it to integrate cutting-edge in vitro diagnostic technologies with innovative drug therapies, ultimately supporting personalized healthcare initiatives. The company’s longstanding history, commitment to scientific excellence, and robust investments in research and development have cemented its reputation as a pioneer in transforming patient care through innovative and differentiated treatment options.

Market Position 
Roche is widely recognized as the world’s largest biotechnology company and a frontrunner in in vitro diagnostics and tissue-based cancer diagnostics. Its consistent investments in R&D—reportedly CHF 12.2 billion in 2020 alone—underscore its commitment to staying at the forefront of scientific innovation. As a market leader, Roche not only drives significant sales in established therapeutic areas such as oncology, immunology, and haematology but also continues to build momentum through a robust pipeline of investigational medicines—including combination regimens and novel therapies—that address unmet medical needs. Its global footprint, with operations in more than 100 countries and a workforce exceeding 100,000 people, further strengthens its strategic position, enabling it to leverage local partnerships while maintaining a world-class centralized R&D infrastructure.

Top-Selling Drugs

Identification of Leading Drugs 
Roche’s portfolio of top-selling drugs is a blend of well-established blockbusters and innovative therapies that have reshaped treatment paradigms in multiple therapeutic areas. The key drugs that have contributed to its dominant market position include: 

- MabThera®/Rituxan® (rituximab): 
One of Roche’s earliest and most recognizable products, MabThera/Rituxan is utilized in the treatment of various haematological malignancies and autoimmune diseases. Over decades, it has become a cornerstone in oncology therapy due to its proven efficacy and long-term clinical data.

- Gazyva®/Gazyvaro® (obinutuzumab): 
A next-generation anti-CD20 monoclonal antibody, Gazyva has been instrumental in treating chronic lymphocytic leukaemia (CLL) and certain types of non-Hodgkin lymphoma. Its improved efficacy over first-generation antibodies has positioned it as a critical drug in Roche’s oncology lineup.

- Polivy® (polatuzumab vedotin): 
Polivy, an antibody-drug conjugate (ADC), represents a major advancement in the treatment of certain blood cancers, particularly diffuse large B-cell lymphoma (DLBCL). The drug’s impressive growth figures—recording a 70% increase in year-over-year sales at times—highlight its rapid adoption in clinical practice.

- Venclexta®/Venclyxto® (venetoclax): 
Developed in collaboration with AbbVie, Venclexta is a BCL-2 inhibitor that has revolutionized treatment for chronic lymphocytic leukaemia (CLL) and other haematologic disorders. Its targeted mechanism of action combined with strong clinical outcomes have made it one of Roche’s flagship products.

- Hemlibra® (emicizumab): 
Hemlibra has redefined the management of haemophilia A by significantly reducing bleeding episodes and improving quality of life for patients. Its inclusion among Roche’s top-selling drugs underlines the company’s commitment to addressing rare but impactful diseases.

- Ocrevus® (ocrelizumab): 
Although not always listed in the same grouping as the blood cancer drugs, Ocrevus is worth special mention for its remarkable performance in the multiple sclerosis (MS) market. Recently highlighted as a key driver for Roche’s projected revenue increase (with sales rising 8% year-over-year), Ocrevus is a cornerstone in the company’s neurology portfolio.

- Tecentriq® (atezolizumab): 
Tecentriq is an immune checkpoint inhibitor used in several oncology indications, including metastatic urothelial cancer, non-small cell lung cancer (NSCLC), and others. Its global approval and expanding label have helped solidify its place in Roche’s innovative oncology offerings.

- Phesgo®: 
Although originally emerging as a supportive therapy in breast cancer, Phesgo has quickly become one of the top growth drivers, with reports of an 81% increase in sales. Approved for HER2-positive breast cancers, it is a combination therapy that enhances patient convenience and clinical outcomes.

Other promising products such as Lunsumio® (mosunetuzumab) and investigational targeted therapies further add to Roche’s diverse portfolio, but the above list represents the drugs that have consistently contributed to top-line revenue and that are recognized as blockbusters in both established and emerging markets.

Sales Data and Revenue 
The strong sales performance of these drugs is reflected in several key financial metrics and growth reports. Analysts have noted that back in 2022, Roche had 16 blockbuster drugs—a figure that nearly doubled from seven in 2012, underscoring a period of accelerated growth driven largely by innovative products. Particularly, a recent Evaluate report predicted that sales of Roche’s blockbusters, including Ocrevus, Tecentriq, and Hemlibra, would contribute significantly to a revenue jump estimated at nearly $4 billion in 2024.

For instance, Polivy showed remarkable momentum with a 70% year-over-year increase, leading to impressive quarterly sales and contributing to Roche’s robust portfolio growth in haematology. Similarly, multiple sclerosis treatment Ocrevus has not only grown steadily but is also anticipated to surge further once its injectable version gains regulatory clearance, potentially pushing its sales upwards of the $2 billion mark.

The combined revenue from these leading drugs places Roche in a position to be rated as the top-selling biotech company globally, with evaluations putting its revenue in the $50–$60 billion range in core markets. Notably, Roche’s revenue performance, when adjusted for constant exchange rates, has shown strong trends—even amid declines in COVID-19-related product sales—with core business growth in pharmaceuticals registering as high as 8–9% in some reports. This trend is a testament to the sustained market demand for its top-selling drugs and aggressive investments in innovative medicines.

Factors Contributing to Sales Success

Therapeutic Areas 
Roche’s sales success across its top-selling drugs is largely driven by its focused therapeutic areas: 

- Oncology: 
A significant portion of Roche’s revenue is derived from oncology products. Drugs such as MabThera/Rituxan, Gazyva, Polivy, and Tecentriq have been designed to disrupt cancer cell proliferation and enhance survival outcomes. This focus on oncology, along with the integration of companion diagnostics, enables precise patient selection and tailored treatments, thereby maximizing efficacy and market uptake.

- Haematology and Immunology: 
The success of drugs like Venclexta and Hemlibra underscores Roche’s commitment to addressing haematologic malignancies and rare blood disorders. These conditions often lack equally effective treatment options, so innovative therapies quickly become blockbusters. Moreover, the high unmet need in these patient populations creates a sustained market demand driven by both clinical utility and patient quality-of-life improvements.

- Neurology: 
With products like Ocrevus for multiple sclerosis, Roche has demonstrated its ability to penetrate the neurology market, which has traditionally been challenging due to complex disease mechanisms and the necessity for personalized treatment plans. Ocrevus’ success is not only a result of its robust clinical profile but also its pivotal role in transforming the prognosis of MS patients.

- Combination Therapies and Multiplicity of Indications: 
Many of Roche’s top-selling drugs are used in combination regimens. For example, the combination of targeted therapies with chemotherapy or immunotherapy strategies (as seen with Tecentriq and Phesgo) further amplifies their clinical benefit and market adoption. This translational approach of combining innovative drugs with proven therapies supports broader indications and increased sales.

Market Demand 
Several factors contribute to the strong market demand for Roche’s top-selling products: 

- Efficacy and Safety: 
The clinical efficacy and safety profiles of these drugs have been robustly established through extensive clinical trials and real-world data. For instance, the long-term effectiveness of MabThera/Rituxan and the innovative mechanism of action of drugs like Venclexta have created a strong trust among healthcare providers and patients alike.

- Global Reach and Personalized Healthcare: 
Roche’s global operations allow it to reach a wide range of patient populations, while its personalized healthcare strategy ensures that each patient receives the right treatment at the right time. By combining pharmaceuticals with diagnostic insights, Roche is able to tailor therapies that precisely match patient profiles, thereby enhancing treatment outcomes and driving high revenue.

- Innovative Delivery Systems and Patient Convenience: 
The development of user-friendly formulations and combination therapies, such as Phesgo for HER2-positive breast cancer which offers more convenient dosing schedules, have proven to boost patient adherence and overall market penetration.

- Regulatory Approvals and Clinical Adoption: 
Consistent regulatory approvals across multiple regions further boost market confidence. Drugs like Ocrevus and Tecentriq have received approvals for multiple indications, significantly broadening their target patient pools, which in turn drives higher sales volumes.

- Collaborations and Strategic Partnerships: 
Roche’s strategic collaborations—such as its partnership with AbbVie for Venclexta—have enabled it to share risks, enhance research capabilities, and expand market access. These collaborations provide financial and operational synergies that reinforce the drug’s market success and revenue growth.

Future Outlook

Pipeline Products 
Looking ahead, Roche is well positioned to maintain its market leadership through an innovative and diversified pipeline. The company continues to invest heavily in promising pipeline candidates designed to boost its future top-seller roster. Notable areas include: 

- Investigation of T-Cell Engaging Bispecific Antibodies: 
Roche is developing T-cell engaging bispecific antibodies such as glofitamab and mosunetuzumab, which target CD20 and CD3, as well as cevostamab, which targets FcRH5 and CD3. These therapies are designed to harness the immune system in fighting haematologic malignancies and could redefine treatment paradigms further.

- Expansion in Immunotherapy: 
The pipeline includes additional immunotherapies like Tecentriq and crovalimab—an anti-C5 antibody engineered to optimize complement inhibition. These candidates represent the next wave of immuno-oncology therapies that promise to expand treatment options and potentially add to Roche’s blockbuster list in the subsequent years.

- New Indications and Formulations: 
Roche’s continuous research into additional indications for its established drugs, such as Ocrevus, where an injectable formulation is under review, demonstrates its commitment to extending the lifecycle of its existing products while meeting new market demands. This approach is expected to offer both incremental revenue growth and diversification of risk.

- Collaboration-Driven Development: 
The company’s pipelines benefit not only from internal R&D but also from strategic external partnerships and acquisitions. By leveraging global expertise and technology, Roche aims to fast-track promising candidates—thus ensuring sustainability of its revenue stream from innovative medicine.

Market Trends and Projections 
The overall market environment for Roche’s top-selling drugs appears positive, with several trends pointing to sustained and robust growth: 

- Growing Global Demand for Personalized Medicine: 
As healthcare systems around the world increasingly embrace personalized medicine, the demand for targeted therapies that integrate diagnostic insights is rising. Roche’s dual focus on diagnostics and therapeutics places it in a prime position to capitalize on this trend. The company’s ability to customize treatment regimens based on real-world data and genomic profiling is expected to drive higher market penetration and sales.

- Shift to Combination Regimens: 
There is an industry-wide trend toward using combination therapies—where multiple drugs are used together to optimize patient outcomes. Roche’s strategy to develop and promote combination regimens (e.g., Polivy combined with other therapies, and Phesgo providing a comprehensive approach in breast cancer treatment) aligns well with market needs and is projected to bolster future sales.

- Economic and Regulatory Landscape: 
Despite potential headwinds such as currency fluctuations, the adverse impact from declining COVID-19 product sales and biosimilar competition, Roche’s core business continues to perform robustly at constant exchange rates. Projections indicate that, even under challenging market conditions, Roche expects mid-single-digit growth in core earnings and revenue for the coming years. With its strategic focus on innovation and sustainable growth, long-term projections for Roche remain optimistic.

- Mergers, Acquisitions, and Strategic Partnerships: 
Future growth is also likely to be supported by smart acquisitions and strategic collaborations, which will provide additional revenue streams and further strengthen the company’s pipeline. As noted by Evaluate and industry analysts, such moves could further solidify Roche’s standing as the leading biotech company by revenue and innovation metrics.

Conclusion 
In summary, Roche’s top-selling drugs are integral to its dominant market position and are characterized by a blend of established blockbusters and innovative new treatments. Key products—such as MabThera®/Rituxan®, Gazyva®/Gazyvaro®, Polivy®, Venclexta®/Venclyxto®, Hemlibra®, Ocrevus®, Tecentriq®, and Phesgo®—play pivotal roles in driving the company’s financial performance and achieving its leadership in oncology, haematology, immunology, and neurology. 

The robust sales data and rapid growth of products like Polivy and Ocrevus illustrate not only the success of Roche’s current portfolio but also underscore the effectiveness of its underlying strategies—ranging from personalized healthcare and companion diagnostics to innovative combination regimens. Factors contributing to this success include extensive investment in R&D, a well-diversified portfolio addressing unmet needs across multiple therapeutic areas, and a well-orchestrated strategy of partnerships and collaborations that extend the company’s market reach globally. 

Looking to the future, Roche is well-positioned to sustain and enhance its success with a dynamic pipeline that promises to bring next-generation therapeutics to market. The ongoing development of T-cell engaging bispecific antibodies, novel immunotherapies, and next-generation formulations reflects both the company's commitment to innovation and its readiness to adapt to emerging market trends. The anticipation of mid-single-digit growth in revenue, bolstered by a strategic focus on pipeline de-risking and acquisitions, projects a promising outlook for the company, ensuring that its top-selling drugs continue to set industry benchmarks. 

In explicit conclusion, Roche’s sustained market leadership is anchored by its top-selling drugs which have demonstrated exceptional clinical performance, robust sales growth, and significant market penetration. These products not only serve as testament to the company’s innovative capabilities but also form the backbone of a forward-looking strategy that emphasizes personalized healthcare, enhanced diagnostic integration, and unwavering commitment to addressing global unmet medical needs. This comprehensive approach ensures that Roche remains at the cutting edge of biopharmaceutical innovation while simultaneously delivering strong financial returns and improved patient outcomes across the globe.

Discover Eureka LS: AI Agents Built for Biopharma Efficiency

Stop wasting time on biopharma busywork. Meet Eureka LS - your AI agent squad for drug discovery.

▶ See how 50+ research teams saved 300+ hours/month

From reducing screening time to simplifying Markush drafting, our AI Agents are ready to deliver immediate value. Explore Eureka LS today and unlock powerful capabilities that help you innovate with confidence.